Sanofi (NASDAQ:SNY) Shares Sold by Kovitz Investment Group Partners LLC

Kovitz Investment Group Partners LLC decreased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 21.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,544 shares of the company's stock after selling 16,658 shares during the period. Kovitz Investment Group Partners LLC's holdings in Sanofi were worth $3,356,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Tidal Investments LLC acquired a new position in Sanofi during the first quarter valued at approximately $228,000. Lantz Financial LLC boosted its position in Sanofi by 23.2% during the 2nd quarter. Lantz Financial LLC now owns 8,054 shares of the company's stock worth $391,000 after purchasing an additional 1,518 shares during the period. Sequoia Financial Advisors LLC increased its holdings in Sanofi by 9.8% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 21,090 shares of the company's stock valued at $1,023,000 after purchasing an additional 1,883 shares in the last quarter. Cooper Financial Group acquired a new position in shares of Sanofi during the second quarter worth about $238,000. Finally, Wedmont Private Capital purchased a new stake in shares of Sanofi in the second quarter worth about $243,000. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Stock Down 0.1 %

Shares of SNY traded down $0.03 during trading on Monday, reaching $48.43. The company's stock had a trading volume of 1,624,415 shares, compared to its average volume of 2,057,410. The company has a market cap of $122.91 billion, a price-to-earnings ratio of 24.72, a P/E/G ratio of 1.23 and a beta of 0.58. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a fifty day moving average of $51.90 and a two-hundred day moving average of $52.12. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm's revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.55 EPS. On average, sell-side analysts predict that Sanofi will post 4.27 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Citigroup upgraded Sanofi to a "strong-buy" rating in a report on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Friday. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of "Moderate Buy" and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.